Kidney Progenitor Exosomes

Overview

Parent Cell: Akira Kidney Progenitor Cells differentiated from UCT-WJ-MSCs | Nephroprotective and anti-inflammatory growth factors and miRNAs for kidney repair and regeneration

What Are Exosomes?

Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.

The Akira Kidney Progenitor Exosomes are derived from kidney progenitor cells (KPCs) produced by stepwise directed differentiation of UCT-WJ-MSCs through intermediate mesoderm and metanephric mesenchyme stages. This recapitulates renal organogenesis, generating cells expressing the key renal progenitor transcription factors SIX2, PAX2, WT1, and LHX1. Podocalyxin (PODXL) expression confirms glomerular progenitor identity.

Kidney progenitor-derived exosomes are enriched with BMP-7 — a critical anti-fibrotic and tubulogenesis-promoting renal morphogen — and HGF, the primary tubular epithelial repair factor. The miR-200 family cargo suppresses epithelial-to-mesenchymal transition (EMT), a central driver of progressive renal fibrosis and tubular atrophy. This preparation addresses the core pathological mechanisms of acute kidney injury (AKI), chronic kidney disease (CKD), and diabetic nephropathy.^[1]

Mechanism of Action

Tubular Epithelial Repair (HGF/EGF Pathway): HGF is the dominant tubular regeneration factor, activating c-Met on proximal tubular epithelial cells to drive proliferation, migration, and restoration of tubular architecture following AKI. EGF provides complementary mitogenic support through EGFR. These growth factors collectively re-establish the proximal tubule epithelium that is most vulnerable to ischemic and nephrotoxic injury.

Anti-Fibrotic Signaling (BMP-7 & miR-200): BMP-7 is a potent endogenous anti-fibrotic morphogen in the kidney, counteracting TGF-β1-driven tubular EMT and interstitial fibrosis. The miR-200 family (miR-200a/b/c, miR-141, miR-429) directly suppresses ZEB1 and ZEB2 — the transcription factors that drive EMT — maintaining tubular epithelial phenotype and preventing fibroblast transition. Together these mechanisms address the fibrotic remodeling that underlies progressive CKD.

Glomerular Protection: VEGF maintains podocyte integrity and glomerular endothelial fenestration — essential for normal filtration barrier function. miR-30a is a podocyte-specific miRNA that suppresses apoptosis and maintains podocyte foot process structure. WT1 and PODXL-associated cargo support the maintenance of the glomerular filtration apparatus, relevant to diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), and membranous nephropathy research.

Renal Inflammation Resolution: miR-146a and miR-21 suppress NF-κB in renal tubular cells and infiltrating macrophages, reducing NLRP3 activation and the IL-1β/TNF-α cascade driving nephron loss. IL-10 from the secretome promotes M2 macrophage polarization in the renal interstitium. Ang-1 stabilizes peritubular capillaries, preventing the microvascular rarefaction that accelerates CKD progression.^[2]

Key Molecular Cargo

Therapeutic Applications

???

Clinical & Preclinical Evidence

???